{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:53:12Z","timestamp":1791276792737,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Onychomycosis is a common chronic fungal infection of the nail unit that may be associated with significant functional impairment and impaired quality of life. Systemic antifungal drugs remain the cornerstone of treatment for moderate-to-severe disease, with continuous oral terbinafine and pulse itraconazole being the most widely used systemic antifungals. Pulse regimens involve intermittent administration of relatively high doses of antifungals with the aim of reducing cumulative drug exposure, treatment costs, and treatment burden while maintaining efficacy. However, the comparative effectiveness of pulse and continuous regimens remains unclear. This narrative review summarizes the current evidence regarding antifungal pulse therapy for onychomycosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted using PubMed and Scopus databases to identify relevant randomized trials, comparative studies, systematic reviews, meta-analyses, observational studies, and case reports\/case series published between March 2001 and April 2026. Evidence relating to treatment regimens, pharmacologic rationale, efficacy, and safety was reviewed and synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The available evidence suggests that pulse therapy is an effective treatment option for onychomycosis. Among the currently available pulse regimens, itraconazole has the strongest supporting evidence and has demonstrated clinical and mycological outcomes comparable to continuous therapy in selected patient populations. Modified pulse schedules, prolonged regimens, and combination approaches incorporating topical antifungal agents have also shown promising results. In contrast, evidence supporting pulse terbinafine is less consistent, with several randomized controlled trials favoring continuous terbinafine, particularly in dermatophyte toenail onychomycosis. Fluconazole administered in weekly regimens appears to be less effective than terbinafine- or itraconazole-based regimens and is generally considered a second-line option. From a safety perspective, pulse and continuous regimens demonstrate safety profiles comparable to those of continuous therapy, with gastrointestinal adverse effects being the most frequently reported events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The current evidence supports continuous terbinafine as the preferred first-line systemic treatment for dermatophyte onychomycosis, whereas pulse itraconazole remains an important alternative for patients who are unable to tolerate terbinafine, have contraindications to its use, or have failed previous therapy. Further well-designed randomized studies with standardized outcome measures and long-term assessment of recurrence are required to better define the optimal role of pulse antifungal therapy in onychomycosis management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-026-04187-4","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:08:02Z","timestamp":1790298482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antifungal pulse therapy for onychomycosis: a narrative review"],"prefix":"10.1007","volume":"82","author":[{"given":"Anushka","family":"Koshy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-0199","authenticated-orcid":false,"given":"Ashwin","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"1","key":"4187_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/1872213X13666191026090713","volume":"14","author":"AKC Leung","year":"2020","unstructured":"Leung AKC, Lam JM, Leong KF et al (2020) Onychomycosis: An Updated Review. Recent Pat Inflamm Allergy Drug Discov 14(1):32\u201345","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"12","key":"4187_CR2","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/14787210.2018.1544891","volume":"16","author":"AK Gupta","year":"2018","unstructured":"Gupta AK, Mays RR, Versteeg SG et al (2018) Update on current approaches to diagnosis and treatment of onychomycosis. Expert Rev Anti Infect Ther 16(12):929\u2013938","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"4187_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2710.2009.01107.x","volume":"35","author":"J Thomas","year":"2010","unstructured":"Thomas J, Jacobson GA, Narkowicz CK et al (2010) Toenail onychomycosis: an important global disease burden. J Clin Pharm Ther 35(5):497\u2013519","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"4187_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaad.2018.03.062","volume":"80","author":"SR Lipner","year":"2019","unstructured":"Lipner SR, Scher RK (2019) Onychomycosis: Clinical overview and diagnosis. J Am Acad Dermatol 80(4):835\u2013851","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4187_CR5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/myc.12396","volume":"58","author":"M Papini","year":"2015","unstructured":"Papini M, Piraccini BM, Difonzo E et al (2015) Epidemiology of onychomycosis in Italy: prevalence data and risk factor identification. Mycoses 58(11):659\u2013664","journal-title":"Mycoses"},{"issue":"3","key":"4187_CR6","first-page":"223","volume":"14","author":"T Rosen","year":"2015","unstructured":"Rosen T, Friedlander SF, Kircik L et al (2015) Onychomycosis: epidemiology, diagnosis, and treatment in a changing landscape. J Drugs Dermatol 14(3):223\u2013233","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"4187_CR7","first-page":"659","volume":"99","author":"R Assadamongkol","year":"2016","unstructured":"Assadamongkol R, Lertwattanarak R, Wannachalee T et al (2016) Prevalence, Risk Factors, and Type of Organism in Fungal Foot Infection and Toenail Onychomycosis in Thai Diabetic Patients. J Med Assoc Thai 99(6):659\u2013664","journal-title":"J Med Assoc Thai"},{"issue":"2","key":"4187_CR8","first-page":"39","volume":"9","author":"F Debbagh","year":"2023","unstructured":"Debbagh F, Babokh F, Sbai M et al (2023) Impact of onychomycosis on the quality of life of patients. Curr Med Mycol 9(2):39\u201344","journal-title":"Curr Med Mycol"},{"key":"4187_CR9","first-page":"1842","volume":"6","author":"DLK Phutane","year":"2025","unstructured":"Phutane DLK, Turankar DAV, Mukhi DJ et al (2025) A Study of Oral Terbinafine (Pulse Therapy) In Combination with Topical Amorolfine Versus Oral Itraconazole (Pulse Therapy) In Combination with Topical Amorolfine for the Treatment of Onychomycosis: A Randomized, Open Label, Parallel Group Study. Int J Med Pharm Res 6:1842\u20131849","journal-title":"Int J Med Pharm Res"},{"issue":"1","key":"4187_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2133.2003.05381.x","volume":"149","author":"D Rigopoulos","year":"2003","unstructured":"Rigopoulos D, Katoulis AC, Ioannides D et al (2003) A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 149(1):151\u2013156","journal-title":"Br J Dermatol"},{"key":"4187_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4103\/0378-6323.37056","volume":"73","author":"A Jaiswal","year":"2007","unstructured":"Jaiswal A, Sharma RP, Garg AP (2007) An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian J Dermatol Venereol Leprol 73:393","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"4187_CR12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1346-8138.2006.00176.x","volume":"33","author":"N Nakano","year":"2006","unstructured":"Nakano N, Hiruma M, Shiraki Y et al (2006) Combination of pulse therapy with terbinafine tablets and topical terbinafine cream for the treatment of dermatophyte onychomycosis: A pilot study. J Dermatol 33(11):753\u2013758","journal-title":"J Dermatol"},{"issue":"5\u20136","key":"4187_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/09546630500420183","volume":"16","author":"S Avner","year":"2005","unstructured":"Avner S, Nir N, Henri T (2005) Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat 16(5\u20136):327\u2013330","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"4187_CR14","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/1346-8138.14607","volume":"45","author":"S Watanabe","year":"2018","unstructured":"Watanabe S, Tsubouchi I, Okubo A (2018) Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol 45(10):1151\u20131159","journal-title":"J Dermatol"},{"issue":"13","key":"4187_CR15","first-page":"2511","volume":"135","author":"\u798f\u7530\u77e5\u96c4 \u65e5\u672c\u76ae\u819a\u79d1\u5b66\u4f1a\u30fb\u65e5\u672c\u533b\u771f\u83cc\u5b66\u4f1a\u5408\u540c\u76ae\u819a\u771f\u83cc\u75c7\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u7b56\u5b9a\u59d4\u54e1\u4f1a","year":"2025","unstructured":"Japanese Dermatological Association and the Japanese Society for Medical Mycology Joint Committee for Preparing Guidelines for Managing Cutaneous Mycoses, Fukuda T, Harada K et al (2025) Hifushinkensho shinryo gaidorain 2025 [Guidelines for the management of cutaneous mycoses 2025]. Nihon Hifuka Gakkai Zasshi 135(13):2511\u20132566 (in Japanese)","journal-title":"\u539f\u7530\u548c\u4fca et al \u76ae\u819a\u771f\u83cc\u75c7\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32025 \u65e5\u672c\u76ae\u819a\u79d1\u5b66\u4f1a\u96d1\u8a8c"},{"issue":"3","key":"4187_CR16","first-page":"24","volume":"17","author":"F Yousefian","year":"2024","unstructured":"Yousefian F, Smythe C, Han H et al (2024) Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics. J Clin Aesthet Dermatol 17(3):24\u201333","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"4187_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1080\/09546634.2019.1623861","volume":"31","author":"M Hamed Khater","year":"2020","unstructured":"Hamed Khater M, Khattab FM (2020) Combined long-pulsed Nd-Yag laser and itraconazole versus itraconazole alone in the treatment of onychomycosis nails. J Dermatological Treat 31(4):406\u2013409","journal-title":"J Dermatological Treat"},{"issue":"6","key":"4187_CR18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1111\/jocd.15660","volume":"22","author":"GA Nasif","year":"2023","unstructured":"Nasif GA, Amin AA, Ragaie MH (2023) Q-switched Nd:YAG laser versus itraconazole pulse therapy in treatment of onychomycosis: A clinical dermoscopic and mycologic study. J Cosmet Dermatol 22(6):1757\u20131763","journal-title":"J Cosmet Dermatol"},{"key":"4187_CR19","doi-asserted-by":"crossref","unstructured":"Dash S, Mohanty P, Nayak MK et al (2026) Efficacy of Itraconazole Pulse Therapy Versus Q-Switched Nd-YAG Laser Versus Combination of Both in the Treatment of Onychomycosis-A Single-Blind Randomized Control Trial. J Cutan Med Surg 30(3):227\u2013232","DOI":"10.1177\/12034754251392072"},{"issue":"5","key":"4187_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3109\/09546634.2016.1151856","volume":"27","author":"A Shemer","year":"2016","unstructured":"Shemer A, Gupta AK, Amichai B et al (2016) An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis (). J Dermatolog Treat 27(5):480\u2013483","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"4187_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.2340\/00015555777476","volume":"77","author":"J Faergemann","year":"1997","unstructured":"Faergemann J, Zehender H, Boukhabza A et al (1997) A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm Venereol 77(1):74\u201376","journal-title":"Acta Derm Venereol"},{"issue":"5 Pt 3","key":"4187_CR22","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/S0190-9622(98)70483-9","volume":"38","author":"J Leyden","year":"1998","unstructured":"Leyden J (1998) Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol 38(5 Pt 3):S42\u201347","journal-title":"J Am Acad Dermatol"},{"issue":"6 Pt 2","key":"4187_CR23","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/S0190-9622(98)70494-3","volume":"38","author":"RC Savin","year":"1998","unstructured":"Savin RC, Drake L, Babel D et al (1998) Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450\u00a0mg) in distal subungual onychomycosis of the fingernail. J Am Acad Dermatol 38(6 Pt 2):S110\u2013116","journal-title":"J Am Acad Dermatol"},{"issue":"6 Pt 2","key":"4187_CR24","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/S0190-9622(98)70493-1","volume":"38","author":"P Rich","year":"1998","unstructured":"Rich P, Scher RK, Breneman D et al (1998) Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450\u00a0mg) in distal subungual onychomycosis of the toenail. J Am Acad Dermatol 38(6 Pt 2):S103\u2013109","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"4187_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/jdv.16101","volume":"34","author":"AK Gupta","year":"2020","unstructured":"Gupta AK, Stec N, Bamimore MA et al (2020) The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 34(3):580\u2013588","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"4187_CR26","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1468-3083.2006.01698.x","volume":"20","author":"AK Gupta","year":"2006","unstructured":"Gupta AK, Gover MD, Lynde CW (2006) Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. J Eur Acad Dermatol Venereol 20(10):1188\u20131193","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"4187_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.36849\/JDD.7323","volume":"22","author":"MA Saleem","year":"2023","unstructured":"Saleem MA, Shah RR, Sharif S et al (2023) Comparing the Efficacy for Pulse Versus Continuous Dose Terbinafine Therapy in Patients With Onychomycosis. J Drugs Dermatol 22(10):1017\u20131020","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"4187_CR28","first-page":"CD010031","volume":"7","author":"S Kreijkamp-Kaspers","year":"2017","unstructured":"Kreijkamp-Kaspers S, Hawke K, Guo L et al (2017) Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev 7(7):CD010031","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4187_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/archderm.138.3.353","volume":"138","author":"B Sigurgeirsson","year":"2002","unstructured":"Sigurgeirsson B, Olafsson JH, Steinsson JB et al (2002) Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138(3):353\u2013357","journal-title":"Arch Dermatol"},{"issue":"3","key":"4187_CR30","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4103\/idoj.idoj_355_22","volume":"14","author":"K Mahajan","year":"2023","unstructured":"Mahajan K, Grover C, Relhan V et al (2023) Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis. Indian Dermatol Online J 14(3):330\u2013341","journal-title":"Indian Dermatol Online J"},{"issue":"5","key":"4187_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/bjd.13358","volume":"171","author":"M Ameen","year":"2014","unstructured":"Ameen M, Lear JT, Madan V et al (2014) British Association of Dermatologists\u2019 guidelines for the management of onychomycosis 2014. Br J Dermatol 171(5):937\u2013958","journal-title":"Br J Dermatol"},{"issue":"10","key":"4187_CR32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/pch\/12.10.875","volume":"12","author":"Antifungal agents for common paediatric infections","year":"2007","unstructured":"Antifungal agents for common paediatric infections (2007) Paediatr Child Health 12(10):875\u2013883","journal-title":"Paediatr Child Health"},{"issue":"3","key":"4187_CR33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1067\/mjd.2001.110644","volume":"44","author":"AK Gupta","year":"2001","unstructured":"Gupta AK, Lynde CW, Konnikov N (2001) Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 44(3):485\u2013491","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4187_CR34","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.51253\/pafmj.v74i5.9366","volume":"74","author":"R Rahmat","year":"2024","unstructured":"Rahmat R, Hussain M, Muzaffar B et al (2024) Comparative Study Between Pulsed and Continuous Itraconazole for the Treatment of Onychomycosis. Pak Armed Forces Med J 74(5):1303\u20131306","journal-title":"Pak Armed Forces Med J"},{"issue":"12","key":"4187_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.53350\/pjmhs20221612745","volume":"16","author":"M Ali","year":"2022","unstructured":"Ali M, Siddiqui MA, Hussain M (2022) Comparative Study Between Pulse Therapy with Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis. Pakistan J Med Health Sci 16(12):745\u2013745","journal-title":"Pakistan J Med Health Sci"},{"issue":"4","key":"4187_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3109\/09546634.2015.1119781","volume":"27","author":"RR Ranawaka","year":"2016","unstructured":"Ranawaka RR, Nagahawatte A, Gunasekara TA et al (2016) Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients. J Dermatological Treat 27(4):364\u2013372","journal-title":"J Dermatological Treat"},{"issue":"10","key":"4187_CR37","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/myc.12799","volume":"61","author":"L Zhang","year":"2018","unstructured":"Zhang L, Xu H, Shi Y et al (2018) An exploration of the optimum dosage and number of cycles of itraconazole pulse therapy for severe onychomycosis. Mycoses 61(10):736\u2013742","journal-title":"Mycoses"},{"issue":"4","key":"4187_CR38","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jaad.2005.04.055","volume":"53","author":"EM Warshaw","year":"2005","unstructured":"Warshaw EM, Fett DD, Bloomfield HE et al (2005) Pulse versus continuous terbinafine for onychomycosis: A randomized, double-blind, controlled trial. J Am Acad Dermatol 53(4):578\u2013584","journal-title":"J Am Acad Dermatol"},{"key":"4187_CR39","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4103\/0378-6323.158634","volume":"81","author":"P Yadav","year":"2015","unstructured":"Yadav P, Singal A, Pandhi D et al (2015) Comparative efficacy of continuous and pulse dose terbinafine regimes in toenail dermatophytosis: A randomized double-blind trial. Indian J Dermatol Venereol Leprol 81:363","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"4187_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/ejdv.ejdv_4_21","volume":"42","author":"EA Taha","year":"2022","unstructured":"Taha EA, Moharam AM, Ladeed AM et al (2022) Therapeutic efficacy of three systemic antifungals in onychomycosis: a randomized clinical trial. Egypt J Dermatology Venerology 42(1):45","journal-title":"Egypt J Dermatology Venerology"},{"key":"4187_CR41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44914","author":"F Etg\u00fc","year":"2023","unstructured":"Etg\u00fc F (2023) Retrospective Analysis of Liver Enzyme Abnormalities in Patients Prescribed Terbinafine and Itraconazole for Onychomycosis. Cureus [Internet]. [cited 2026 May 13] https:\/\/doi.org\/10.7759\/cureus.44914","journal-title":"Cureus [Internet]"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04187-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04187-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04187-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:27:48Z","timestamp":1791275268000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04187-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4187"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04187-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"28 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Since this was a narrative review, evaluating data from published literature, ethics approval is not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"257"}}